The rise of large language models (LLMs) like ChatGPT and Perplexity promises to revolutionize healthcare. However, a crucial question remains: should doctors blindly accept their outputs? This review delves into the potential benefits and drawbacks of integrating LLM-generated text into clinical practice. We analyze how these tools can support tasks, identify potential biases, and explore the importance of physician oversight and critical thinking.
The healthcare landscape is brimming with innovation. Artificial intelligence (AI) is making significant strides, and large language models (LLMs) like ChatGPT and Perplexity stand at the forefront. These AI tools possess remarkable capabilities, from generating medical summaries to assisting with literature reviews. But can doctors simply agree with their outputs? This review critically examines the role of LLM-generated text in healthcare, exploring its potential benefits and limitations.
ChatGPT and Perplexity offer a plethora of potential benefits for healthcare professionals:
Enhanced Workflow Efficiency: LLMs can automate administrative tasks like generating reports and summarizing medical records, freeing up valuable physician time for patient care.
Improved Information Access: These AI tools can comb through vast amounts of medical literature, summarizing key findings and identifying relevant research for informed clinical decision-making.
Personalized Medicine Support: By analyzing patient data, LLMs can assist in generating personalized treatment plans and educational materials tailored to individual needs.
However, alongside these benefits lie significant limitations that demand cautious consideration:
AI Bias and Accuracy: LLMs rely on training data, which can harbor biases that may lead to inaccurate or discriminatory outputs.
Black Box Problem: The inner workings of LLMs can be opaque, making it challenging for doctors to understand the reasoning behind their recommendations.
Ethical Dilemmas: The use of AI in medicine raises ethical concerns regarding patient privacy, informed consent, and the potential for overreliance on AI outputs.
LLMs should not replace doctors; rather, they should serve as powerful tools. Physicians must maintain critical thinking skills and exercise oversight when utilizing LLM-generated text:
Evaluating for Bias: Doctors must be aware of potential biases within LLM outputs and critically assess their accuracy and implications for patient care.
Verifying Information: LLM-generated text should never be taken as definitive. Doctors must verify findings through independent research and clinical judgment.
Understanding the Limitations: Physicians need a clear understanding of LLM limitations and utilize them as supplementary tools, not replacements for their own expertise.
ChatGPT and Perplexity present exciting possibilities for healthcare. However, it is crucial to use them judiciously. By acknowledging their limitations and maintaining robust physician oversight, these AI tools can empower doctors, ultimately leading to improved patient care. Further research and development are essential to enhance LLM transparency, mitigate bias, and ensure responsible integration into clinical practice.
1.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
2.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
3.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
4.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
5.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
1.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
2.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
3.
Precision Cancer Risk Mitigation Strategies
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation